Search

Your search keyword '"Stellbrink, HJ"' showing total 272 results

Search Constraints

Start Over You searched for: Author "Stellbrink, HJ" Remove constraint Author: "Stellbrink, HJ"
272 results on '"Stellbrink, HJ"'

Search Results

1. Non-AIDS defining cancers in the D:A:D Study - time trends and predictors of survival: A cohort study

2. Measuring recent thymic emigrants in blood of normal and HIV-1-infected individuals before and after effective therapy.

3. The extent of B‐cell activation and dysfunction preceding lymphoma development in HIV‐positive people†

4. Gender differences in the use of cardiovascular interventions in HIV?positive persons; the D:A:D Study

7. Uptake and effectiveness of two-drug compared with three-drug antiretroviral regimens among HIV-positive individuals in Europe

8. Establishing a hepatitis C continuum of care among HIV/hepatitis C virus-coinfected individuals in EuroSIDA

9. Immediate Versus Deferred Switching From a Boosted Protease Inhibitor-based Regimen to a Dolutegravir-based Regimen in Virologically Suppressed Patients With High Cardiovascular Risk or Age >= 50 Years: Final 96-Week Results of the NEAT022 Study

10. Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study

11. HIV-induced immune activation - pathogenesis and clinical relevance

12. High prevalence of comorbidities and use of concomitant medication in treated people living with HIV in Germany - results of the BESIDE study.

13. High prevalence of recreational and illicit drug use in German people living with HIV with a potential for drug–drug interactions with antiretroviral therapy.

14. Tuberculosis among HIV-positive patients across Europe: changes over time and risk factors

15. Langzeiterfolge bei 172 hochmalignen Nicht-Hodgkin-Lymphomen unter besonderer Berücksichtigung älterer Patienten*

16. Cumulative and current exposure to potentially nephrotoxic antiretrovirals and development of chronic kidney disease in HIV-positive individuals with a normal baseline estimated glomerular filtration rate: a prospective international cohort study

17. Long-term effectiveness of unboosted atazanavir plus abacavir/lamivudine in subjects with virological suppression: A prospective cohort study

18. Bone mineral density and inflammatory and bone biomarkers after darunavir-ritonavir combined with either raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults with HIV-1: a substudy of the NEAT001/ANRS143 randomised trial

19. Variable impact on mortality of AIDS-defining events diagnosed during combination antiretroviral therapy : not all AIDS-defining conditions are created equal

20. Development of a definition for rapid progression (RP) of renal function in HIV-positive persons:the D:A:D study

21. Once‐daily S/GSK1349572 combination therapy in antiretroviral‐naïve adults: rapid and potent 24‐week antiviral responses in SPRING‐1 (ING112276)

22. 96-Week results of abacavir/lamivudine versus tenofovir/emtricitabine, plus efavirenz, in antiretroviral-naive, HIV-1-infected adults: ASSERT study

23. Vitamin D and clinical disease progression in HIV infection: results from the EuroSIDA study

24. Estimating prevalence of accumulated HIV-1 drug resistance in a cohort of patients on antiretroviral therapy

25. A comparison of the long-term durability of nevirapine, efavirenz and lopinavir in routine clinical practice in Europe: a EuroSIDA study

26. Results from the German etravirine early access programme

27. History of viral suppression on combination antiretroviral therapy as a predictor of virological failure after a treatment change

28. Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study

29. Relationship between current level of immunodeficiency and non-acquired immunodeficiency syndrome-defining malignancies

30. Serious Fatal and Nonfatal Non-AIDS-Defining Illnesses in Europe

31. Phylogenetische Analyse akuter HCV Genotyp 4 Infektionen bei HIV-positiven Männern, die Sex mit Männern (MSM) haben

32. High prevalence of the metabolic syndrome in HIV-infected patients: impact of different definitions of the metabolic syndrome

33. Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients

34. Dialysis and renal transplantation in HIV-infected patients: a European survey

35. Does short-term virologic failure translate to clinical events in antiretroviral-naïve patients initiating antiretroviral therapy in clinical practice?

36. HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies

37. Changes over time in risk factors for cardiovascular disease and use of lipid-lowering drugs in HIV-infected individuals and impact on myocardial infarction

38. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration

39. Immuno-virological discordance and the risk of non-AIDS and AIDS events in a large observational cohort of HIV-patients in Europe

41. Comparison of single and boosted protease inhibitor versus nonnucleoside reverse transcriptase inhibitor-containing cART regimens in antiretroviral-naïve patients starting cART after January 1, 2000

42. Increasing numbers of acute hepatitis C infections in HIV‐infected MSM and high reinfection rates following SVR

43. The SENSE trial: etravirine shows lower prevalence and severity of neuropsychiatric adverse events compared to efavirenz in treatment-naïve patients

46. Die Behandlung sexuell übertragener akuter Hepatitis C Infektionen bei HIV-positiven Patienten

47. Measuring recent thymic emigrants in blood of normal and HIV-1-infected individuals before and after effective therapy

49. Late presentation for HIV diagnosis and care in Germany.

50. Incidence of tuberculosis among HIV-infected patients receiving highly active antiretroviral therapy in Europe and North America

Catalog

Books, media, physical & digital resources